Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509369 | 0.88 | NPC1 (0.56) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL3748833 | 0.85 | POLB (0.60) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL3064262 | 0.82 | MEN1 (0.57) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL31430551 | 0.80 | POLB (0.53) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL10173106 | 0.80 | RAB9A (0.65) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL31490986 | 0.80 | RAB9A (0.65) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL12459201 | 0.79 | RAB9A (0.57) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL13543033 | 0.78 | SSTR5 (0.52) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL2420144 | 0.78 | RAB9A (0.61) | POLBRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL11443651 | 0.78 | MEN1 (0.62) | POLBRAB9ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242278-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-1473286-B1 | PROCESS FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI | 2009-08-27 | — | — | US | disclosed |
| US-7554000-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| CN-1303043-C | Process for producing biaryl compound | SUMITOMO CHEMICAL CO (JP) | 2007-03-07 | — | — | CN | disclosed |
| US-20050096471-A1 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1473286-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-4837308-A | Process for the preparation of azo compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| EP-0201892-B1 | METHOD OF MAKING AZO COMPOUNDS | BAYER AG (DE) | 1989-03-08 | — | — | EP | disclosed |
| EP-0201892-A1 | Method of making azo compounds | BAYER AG (DE) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | POLB 909/4885RAB9A 2254/4885NPC1 4102/4885 |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | POLB 909/4885RAB9A 2254/4885NPC1 4102/4885 |
| US-20050096471-A1 | Process for producing biaryl compound | PPOX, CAT, TYR | POLB 909/4885RAB9A 2254/4885NPC1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.